CRSP NASDAQ
CRISPR Therapeutics AG
1W: +3.2%
1M: -4.8%
3M: +8.0%
YTD: -4.3%
1Y: -23.9%
3Y: +33.3%
5Y: -48.7%
$51.47
+2.46 (+5.02%)
Weekly Expected Move ±6.6%
$43
$46
$49
$53
$56
Credit Risk of going bust: lower than 50% of companies Debt: 13.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.70 (down 99%), CRISPR Therapeutics AG would be worth roughly what it owes.
Total debt $783.7M against a stock market value of $4.98B.
Distance to default 5.14 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $293.1M (short-term plus half of long-term), stock volatility 57.2%; Altman Z'' 3.71. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $783.7M against a stock market value of $4.98B.
Distance to default 5.14 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $293.1M (short-term plus half of long-term), stock volatility 57.2%; Altman Z'' 3.71. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
14 relationships12
As Filer
counterparties named
2
As Counterparty
mentioned by others
1
Rel. Types
2021-04-20
Earliest Filing
2025-05-19
Latest Filing
partner: 12
Counterparties (Filed by CRSP)
12 relationshipsCompanies named in CRSP's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Sirius Therapeutics | — | partner | Partnered with CRISPR Therapeutics AG for collaboration, option, and license agreement regarding siRNA technology target | 2025-05-19 | View |
| Vertex Pharmaceuticals Incorporated | VRTX | partner | Amendment to joint development and commercialization agreement for exa-cel | 2023-12-13 | View |
| Vertex Pharmaceuticals (Europe) Limited | VERX | partner | Amendment to joint development and commercialization agreement for exa-cel | 2023-12-13 | View |
| CRISPR Therapeutics AG | CRSP | partner | Amendment to joint development and commercialization agreement for exa-cel | 2023-12-13 | View |
| CRISPR Therapeutics Limited | CRSP | partner | Amendment to joint development and commercialization agreement for exa-cel | 2023-12-13 | View |
| CRISPR Therapeutics, Inc. | CRSP | partner | Amendment to joint development and commercialization agreement for exa-cel | 2023-12-13 | View |
| TRACR Hematology Ltd | — | partner | Amendment to joint development and commercialization agreement for exa-cel | 2023-12-13 | View |
| Vertex Pharmaceuticals Incorporated | VRTX | partner | Amended joint development and commercialization agreement for CTX001 | 2021-04-20 | View |
| Vertex Pharmaceuticals (Europe) Limited | VERX | partner | Signatory to the amended joint development and commercialization agreement | 2021-04-20 | View |
| CRISPR Therapeutics Limited | CRSP | partner | Signatory to the amended joint development and commercialization agreement | 2021-04-20 | View |
| CRISPR Therapeutics, Inc. | CRSP | partner | Signatory to the amended joint development and commercialization agreement | 2021-04-20 | View |
| TRACR Hematology Ltd | — | partner | Signatory to the amended joint development and commercialization agreement | 2021-04-20 | View |
Mentioned As Counterparty
2 mentionsOther companies that named CRSP in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| NKTX Nkarta, Inc. | partner | Strategic partner for co-developing and co-commercializing gene-edited cell therapies and licensing gene-editing technol | 2021-05-06 | View |
| VRTX VERTEX PHARMACEUTICALS INC / MA | partner | Joint development and commercialization partner for CTX001 | 2021-04-20 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-19 | Officer/Director Change; Exhibits | View | |
| 2026-08-03 | Earnings Release; Exhibits | View | |
| 2026-06-04 | Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-05-04 | Earnings Release; Exhibits | View | |
| 2026-03-16 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2026-03-11 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Other Events | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-15 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-26 | Other Events | View | |
| 2025-06-09 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-05-19 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-26 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-02-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-03 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR